Steve Shadowen served as a panel member at an event put together by the ABA's Section on Antitrust law, discussing how antitrust courts should address cases challenging product hopping practices.

Steve Shadowen Discusses Antitrust Implications of Product Hopping

On March 13, 2015, Steve Shadowen served as a panel member at an event put together by the American Bar Association's Section on Antitrust law, discussing how antitrust courts should address "product hopping"—the phenomenon where a branded pharmaceutical company tries to convert patients from a branded drug facing patent expiration to a newer version with different attributes that remain patented.  The practice is highlighted in one of Hilliard & Shadowen's monopolization cases, In re: Suboxone Antitrust Litigation.

The ABA's event brought together leading litigators from both sides of these issues to discuss when product hopping raises antitrust issues and how courts should address them.